Researchers we empower:
Developing the Future of Preclinical Research
We envision a world where animal experiments are obsolete. To make this a reality we are starting with eliminating renal toxicity for compounds entering clinical stages of drug development. This ambition is driven by our human renal ciPTEC cell lines and its use within our growing global network of research professionals. We believe that researchers deserve the best tools available in order to deliver their best work.
Realize Impactful Kidney Research
Build upon extensive
Our cell models are validated during extensive partnerships with universities and the pharmaceutical industry.
Gather detail on renal
ciPTEC is a human renal cell line that mimics the proximal tubule cells of the kidney accurately.
Cell4Pharma’s ciPTEC technology can predict renal adverse effects in early stages of drug development.
ciPTEC Cell Lines
Cell4Pharma tackles your ADME-tox issues based upon our ciPTEC platforms:
human renal proximal tubule epithelial cell lines stably expressing relevant renal drug transporters.
renal cell line
Introducing temperature sensitive genes into a human renal proximal tubule cell allowed us to develop ciPTEC: a human renal cell line with unlimited proliferation capacity at 33°C and highly resemblance with the human kidney at 37°C.
Functional expression of
Relevant Renal Drug Transporters
Just as in the in vivo situation, Cell4Pharma’s ciPTEC is able to transport a wide range of compounds, including organic anions and organic cations. This characteristic is required in order to predict drug-induced kidney injury during drug development and is facilitated by the expression of relevant drug transporters.
Highly Predictive on
The expression of relevant drug transporters leads to active transport of compounds passing the cell membrane. Using fluorescent markers, drug-drug-interaction studies were developed in collaboration with the pharmaceutical industry. Moreover, the exposure to known toxicants in validation studies resulted in the detection of a range of biomarkers for renal toxicity.
Using a multi-parametric high content screening assay developed in collaboration with Astrazeneca we could demonstrate that ciPTEC-OAT1 was highly sensitive and specific using a set of 62 compounds.
Because the cell line is robust in culture, the research leads to reliable results. As far as I am concerned, there is currently no kidney epithelial cell line available with an equally good predictive value for the human kidney.
Perfused tubular structures in the OrganoPlate platform established with the ciPTEC cell line showed great performance in predicting renal toxicity of tested compounds and drugs. The specific transporter overexpression lines are valuable in understanding a compound’s mode of action or determining potential drug-drug interactions.
The ciPTEC mimics primary renal cells, but you can culture them for a long time without losing their properties. The expression of transporters gives a more accurate response to drugs and toxins. The cells grow fast and are easy to handle.
ciPTEC is a well-accepted in vitro model to screen compounds for their DIKI potential.